Europe Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2030

Europe Prescription Digital Therapeutics (PDTx) Market Analysis and Size

Prescription digital therapeutics have been developed as a boon for a number of diseases such as substance use disorder (SUD), ADHD, major depressive disorder (MDD), opioid use disorder (OUD), insomnia, epilepsy, multiple sclerosis, autism spectrum disorder, and cardiovascular disease. Patients with several unmet requirements may find prescription digital therapies to be the most vital aspect of their lives. Presently, numerous research & clinical studies are going on which is anticipated to create a competitive advantage for several manufacturers to develop new and innovative technology.

 Data Bridge Market Research analyses a growth rate in the prescription digital therapeutics (PDTx) market in the forecast period 2023-2030. The expected CAGR of prescription digital therapeutics (PDTx) market is tend to be around 21.4% in the mentioned forecast period. The market value is USD 179.5 million in 2022, and it would grow upto USD 846.8 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Europe Prescription Digital Therapeutics (PDTx) Market Scope and Segmentation

Market Definition

Prescription digital therapies is a kind of software that is used to treat numerous ailments. Artificial intelligence, diverse algorithms, and virtual reality are widely used to develop these therapeutic instruments. Patients sometimes use prescription digital therapeutics software and services to get any form of treatment they needed it.  These medicines are tightly regulated by the FDA and other regulatory authorities and can only be used with an appropriate prescription from a doctor.

Europe Prescription Digital Therapeutics (PDTx) Market Dynamics

Drivers

• Increasing incidence of Chronic Diseases

The increasing prevalence of chronic diseases is a primary factor boosting the prescription digital therapeutics (PDTx) market's growth rate during the forecast period. According to the World Health Organization (WHO), around 463 million adults will have diabetes in 2020. In 2021, 35.2% of the European population aged 16 years and above reported a long-term illness. The number of people who are surviving with cancer has also been growing. At present, 16–17 million European citizens are expected to either be in the treatment phase for cancer or are in post-treatment phase, and this number will also increase significantly over the next 10–20 years. Therefore, this factor increases the growth of the market.

• Developing Pipeline for Potential Products

A major pipeline of potential items estimated to be released throughout the forecast period is expected to benefit the growth of prescription digital therapeutics (PDTx). For instance, Pear-011 (anxiety GAD), Pear-015 (depression MDD), which are used in the treatment of adults suffering from chronic insomnia and depression, and CT-155 (schizophrenia), CT-152 (major depressive disorder), which are used in the treatment of adults with depression and schizophrenia, are products of potential pear therapeutics clinical therapeutics products in phase III. This factor improves the market growth.

Opportunities

• Increased Research Activities

The research activities associated with the prescription digital therapeutics is increasing and thus boosting the growth of the marketthus boosting the market. For instance, NuvoAir AB was certified as class Im medical device in August 2020. The company has achieved this certification due to its advanced features involving certified bluetooth spirometer, combined with the healthcare portal and connected patient app. This certification has improved the brand value among the physicians and patients. Thus, this factor created much opportunity for the market growth.

• Growing Adoption of Software for Diabetes

The software for diabetes is anticipated to increase the market as the world is having major population suffering from the diabetes and is the primary cause of death. As per a survey, 463 million populations suffering from diabetes and this date is growing continuously at a rapid rate,  because of this, Europe health expenditure on diabetes is also increasing and multiple research is going on to find the new and easy way to treat the patients. Therefore, this factor helps to create much opportunities for the growth of the market.

Restraints/Challenges

• Security and Data Management

PDTx transmits information over the internet, hence the risk of unauthorized access and manipulation of these solutions could threaten product confidence and patient care. The FDA has issued guidance on cybersecurity, labelling, and documentation for pre-marketing submissions, but several agencies do not currently require pre-market medical device safety audits to be completed. It is the complete responsibility of the device manufacturers to define the level of cybersecurity risk related with their products and perform actions to reduce this risk. This impedes the market growth.

• Difficulty in Adaptation of Digital Therapeutics by Doctors

Not all doctors and providers are not familiar with the increasing digitization. Doctors and healthcare professionals should get familiar with digital therapy solutions before using their mass adoption. They should analyze the results of clinical trials before recommending the solutions to their patients. To perform this, few DTx companies opt for pharmaceutical model wherein partnerships with distributors are used to inform doctors about clinical trial results, new solutions, and decisions. Thus, this hampers the market growth.

This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Biofourmis announced that its Biovitals platform had been widely used by the Ministry of Health (MOH) in Singapore to observe the health for COVID-19 patients. This initiative enabled the nurses and clinicians to diagnose the disease symptoms early, enabling patients to achieve effective treatment. Thus, this initiative improved the company’s revenue by increasing the adoption rate during COVID-19 pandemic. 

Europe Prescription Digital Therapeutics (PDTx) Market Scope

The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application, patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism

• Input Mechanisms
• Output Mechanisms

Category

• Medication Augmentation
• Medication Replacement

Treatment

• Outpatient Treatment
• Monotherapy

Software

• Software for Respiratory Conditions
• Software for Mental Health
• Software for Opioid Use Disorder
• Software for Diabetes
• Others

Services

• Behavioral Microservices
• Medical Microservices

App Accessibility

• Android
• iOS
• Windows

App Type

• Native Apps
• Web Apps

Application

• Substance Use Disorder (SUD)
• Opioid Use Disorder (OUD)
• Attention Deficit/Hyperactivity Disorder (ADHD)
• Alzheimer’s Disease
• Major Depressive Disorder (MDD)
• Insomnia
• Epilepsy
• Movement Disorder
• Multiple Sclerosis
• Migraine
• Autism Spectrum Disorder
• Oncology
• Inflammation
• Respiratory
• Cardiovascular
• Pain Management
• Metabolic Conditions
• Others

Patients

• Children
• Adults

Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights

The prescription digital therapeutics (PDTx) market is analyzed and market size insights and trends are provided by mechanism, category, treatment, software, services, app accessibility, app type, application, patients as referenced above.

The major countries covered in the prescription digital therapeutics (PDTx) market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Germany is anticipated to grow with the highest CAGR in the forecast period as the application of prescription digital therapeutics is increasing across several European countries with technological advancement in software. Furthermore, the increasing number of domestic companies operating in the market is also boosting the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Europe Prescription Digital Therapeutics (PDTx) Market Share Analysis

The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Prescription digital therapeutics (PDTx) market

Key players operating in the prescription digital therapeutics (PDTx) market include:

• ResMed (U.S.)
• SAMSUNGHEALTHCARE (South Korea)
• Biofourmis (US)
• Novartis AG (Switzerland)
• Medtronic (Ireland)
• Pear Therapeutics, Inc. (U.S.)
• Voluntis (France)
• Omada Health, Inc. (U.S.)
• GAIA AG (Germany)
• Welldoc’s Bluestar (U.S.)
• Solera Network (U.S.)
• Akili Interactive Labs, Inc. (U.S.)
• Better Therapeutics, LLC (U.S.)
• BigHealth (U.S.)
• Biofourmis (U.S.)
• Click Therapeutics, Inc. (U.S.)
• Happify, Inc. (U.S.)
• Limbix Health, Inc. (U.S.)
• Naturalcycles Nordic AB (Sweden)
• NuvoAir AB (Sweden)
• Sensyne Health plc. (U.K.)
• Xealth (U.S.)

SKU-58520